May 12, 2020

"A New Parenteral Treatment for a Severe C. difficile Infection" hosted by Nancy C. Caralla

Join us with our two guests: Dr Yannick Pletan, Independent Director Clinical development specialist,Doctor of medicine, and Georges Gaudriault, Scientific Director, PhD in molecular pharmacology. Both Dr. Pletan and Gaudriault will introduce and discuss DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics, announced the inclusion of the first patient in the Phase II trial testing DNV3837. DNV3837 targets the treatment of Clostridioides difficile (C. diff. ) infections (CDI), a disease classified as a priority by the WHO and one of the global leading causes of healthcare-related infections. DNV3837 is an intravenous antibiotic that, when converted to its active form DNV3681, crosses the gastrointestinal barrier and accumulates in the intestinal lumen, allowing it to precisely target the infection site.

Listen to the replay…

Read the transcript (in French)